Introduction
Brain tumors can cause intractable seizures. Gliomas, which are the most common type of brain tumor, account for the majority of tumor-associated seizures [1] [2] [3] . Patients with low-grade gliomas (LGGs) often experience secondary epileptic seizures as their chief complaint [4] [5] [6] . In contrast, patients with glioblastomas, the most malignant type of glioma, are unlikely to experience seizures as the tumor progresses [7, 8] . Thus, identifying the mechanisms underlying the generation of LGG-related seizures is critical for determining the prognoses of and appropriate treatment strategies for patients with LGGs.
The genetic background of brain tumors has been linked to the tumor's ability to invade the normal brain tissue and peritumoral microenvironment [9, 10] . Moreover, since epileptic seizures are generated as a result of chronic damage to neurons, the genetic characteristics of the tumor may be related to the epileptogenesis in patients with LGGs [11] . Indeed, evidence suggests that genes, which are associated with glutamate transporter expression, synaptic transmission, and cell apoptosis, are involved in the generation of LGG-related seizures [12] [13] [14] . However, the molecular profiles that contribute to glioma-induced seizures are currently unclear [13, 15] .
Identifying seizure-associated genes in gliomas requires the gene expression of patients with and without seizures to be compared using a whole-genome analysis and large number of tumor samples. Therefore, in the current study, we employed a whole-transcriptome sequencing analysis based on the data from the Chinese Glioma Genome Atlas (CGGA, http://www.cgga.org.cn, a pure Chinese population dataset). Correlations between the expression of specific genes and LGG-related epilepsy were investigated. Furthermore, the results of this study were validated with RNA sequence data from an independent database, The Cancer Genome Atlas (TCGA, cancergenome.nih.gov, a mixed population with mostly Caucasian individuals). The prognostic roles of the identified genes were also investigated.
Methods

Data collection
A testing group consisting of 86 patients with LGGs (World Health Organization grade II) was enrolled in this study. The clinical information of patients and the RNA sequencing data obtained from CGGA database. All samples from the patients in the testing group were collected during the initial brain surgery. A validation group of patients was collected from the TCGA database. The current study was approved by the ethics committee of Beijing Tiantan Hospital, and all participants provided informed consent allowing their information to be collected in the database and analyzed.
Assessment of seizure occurrences and outcomes
Tumor-associated epileptic seizures were identified based on the clinical presentation of the patients. LGG-associated epilepsy was defined as a history of one or more seizure presentation in patients with LGGs [2] . Seizure types, including partial and generalized seizures, were classified according to the seizure terminology defined by the International League Against Epilepsy [16] . Patients were placed in either the seizure or non-seizure group based on their presentations.
The seizure outcome was also assessed during patient followup at 6 months after surgery. In this study, the Engel Epilepsy Surgery Outcome Scale was used to describe the seizure outcomes, which were classified as follows: Class I, free of disabling seizures; Class II, rare disabling seizures; Class III, worthwhile improvement; or Class IV, no worthwhile improvement or a worsened condition [17] .
RNA sequencing and data analyses
CGGA RNA sequencing was performed as previously described [18] . Briefly, frozen tumor samples were disrupted and homogenized with a QIAshredder and pestle (Qiagen, Germany). Libraries were sequenced on the Illumina HiSeq 2000 platform using the 101-bp pair-end sequencing strategy. Short sequence reads were aligned to the human reference genome (Hg19Refseq) using the Burrows-Wheeler Aligner (version 0.6.2-r126). The reads per kilobase transcriptome per million method was used to assess the gene expression [19] . Normalization allowed the direction of gene expression to be compared between individual cases. In addition, TCGA RNA sequencing data and the corresponding genetic profiles [20] were collected from the online TCGA database and used as the validation group in this study.
Statistical analysis
The mean expression of all genes was calculated and compared between the seizure and non-seizure groups using t-statistics. The clinical characteristics associated with the occurrence of seizures were identified using chi-squared tests. A univariate analysis was performed to identify the significant (p 0.05) risk factors for LGGassociated seizures. The prognostic role of the gene expression (high vs. low) was investigated with log-rank tests and demonstrated in Kaplan-Meier curves.
Results
Clinical characteristics
A group of 86 patients with LGGs were reviewed, including 35 (40.7%) with astrocytomas, 17 (19.8%) with oligodendrogliomas, and 34 (39.5%) with oligoastrocytomas. The mean age of the patients at diagnosis was 39 years (range: 21-62 years). Preoperative epileptic seizures occurred in 57 (66.3%) patients, while 29 patients were free of tumor-related seizures. Generalized seizures secondary to the brain tumor were observed in 38 (66.7%) of the patients with seizures. Partial seizures were observed in 6 (10.5%) cases with complex partial seizures and 13 (22.8%) cases with simple partial seizures. There were 82 (95.3%) patients who underwent radiotherapy, while only 6 (7.0%) cases underwent additional chemotherapy.
Gene analysis
Gene data based on RNA sequencing were collected from the CGGA database. The gene expression patterns of the tumor samples were compared between patients with tumor-associated seizures and those without seizures. The results revealed that 370 genes were differentially expressed between the two groups (p 0.05). In addition, several genes from the TCGA database were differentially expressed between the seizure and non-seizure groups (Supplementary material 2). One of the identified genes, Forkhead Box O4 (FOXO4), is reportedly associated with tumor development [21, 22] . Therefore, we focused our investigation on the association between FOXO4 expression and tumor-associated seizures.
FOXO4 mRNA expression in the CGGA dataset
In this study, the expression of FOXO4 was significantly lower in patients with tumor-associated seizures than it was in patients without seizures (5.80 AE 0.35 vs. 7.17 AE 0.53, p = 0.026, t-test; Fig. 1A ). Several factors, including, a younger age at diagnosis (<40 years), low FOXO4 expression, and frontal-region involvement were identified as being associated with the occurrence of seizures. None of the other clinical characteristics was significantly associated with the occurrence of seizures. In addition, the patient's age (<40 years), low FOXO4 expression, and frontalregion involvement were identified as independent risk factors for tumor-associated seizures (Table 1) .
Validation of FOXO4 expression in the TCGA dataset
Using the TCGA dataset, we collected the gene expression data (1993 to 2013) from patients with LGGs, and cases with available clinical data (n = 238) were used as the validation group in the current study. We then analyzed the association between FOXO4 expression and the occurrence of seizures. Similarly, significantly lower FOXO4 expression was identified in patients with seizures compared to in patients without seizures (9.55 AE 0.06 vs. 9.79 AE 0.07, p = 0.005, t-test; Fig. 1B ). The identified differentiation in the CGGA dataset was thus validated by the TCGA dataset. The association between seizure occurrence and other clinical characteristics in TCGA dataset was demonstrated (supplementary Table 1 ). Other genes found to be associated with the occurrence of seizures in both CGGA and TCGA dataset included P4HA1, LPP, APPL2, PDAP1, and RINT1 (their functions are listed in supplementary Table 2 ).
Seizure outcomes and FOXO4 expression
The prognostic role of FOXO4 in the seizure outcome was investigated using the CGGA database. As mentioned above (Section 2.2.), seizure outcomes were assessed using the Engel Epilepsy Outcome Scale at 6 months after surgery (available in 81 cases). We found that the expression of FOXO4 was significantly associated with the Engel classification in patients with LGGs at 6 months after tumor resection (p = 0.018, Mann-Whitney U test; Fig. 2 ). Specifically, high FOXO4 expression was noted in patients with low Engel classifications (better seizure outcomes). Therefore, FOXO4 significantly influenced the seizure outcomes in patients with
LGGs. In addition, generalized epilepsy (p = 0.014) and gross total resection (p = 0.005) were found to be associated with a favorable seizure outcome.
Discussion
RNA sequencing technology is frequently used to investigate the biological activity of tumors. Using various large-scale databases, genetic alternations have been detected in brain tumors and these changes were found to be related to specific features, such as epileptogenesis [14] . However, few reports on the molecular mechanisms of tumor-induced seizures exist. In the current study, we used the CGGA database to collect the RNA sequence data and corresponding clinical information from 85 glioma samples. By performing quantitative assessments of gene expression, we identified a potential association between FOXO4 expression and LGG-associated epilepsy; the result was further validated by comparing the CGGA samples to the glioma samples from the TCGA database.
The association between epileptic seizures and LGGs is well known. Here, the incidence of tumor-associated seizures was 66.3% (57/86), which is consistent with the seizure incidence (68.9%) that was reported previously in a study of the Chinese population [23] . Unfortunately, the molecular mechanisms of tumor-associated seizures remain unclear [6] .
The association between gene expression and seizure occurrences had been investigated by previous studies [6, 24, 25] . The gene mutation of isocitrate-dehydrogenase 1 (IDH1) was found to be an independent risk factor for seizures in patients with LGGs [26, 27] . Additionally, a tumor suppressor gene (leucine-rich glioma inactivated 1) was identified as a seizure-related gene that participates in the control of non-ion channels in the peritumoral region in temporal lobe epilepsy [28, 29] . Moreover, the high expression of RINT1 (associated with DNA repair) was found to predict increased preoperative seizures and poor postoperative seizure outcomes in patients with LGGs [30] . Genetic alterations regarding immune function and synaptic transmission have also been linked to epilepsy secondary to tumor involvement [25, 31] . Nevertheless, the genetic correlations of seizure occurrences in gliomas remain unknown.
The forkhead box transcription factor family is comprised of four highly related members (FOXO1, FOXO3, FOXO4 , and FOXO6), which play important roles in cancer growth and metastasis [21, 22] . FOXO4 has been identified as a novel tumor suppressor gene in a variety of neoplasms, such as in renal carcinoma [32] , gastric cancer [33, 34] , and cervical carcinoma [35] . However, the role FOXO4 plays in the tumorigenesis of gliomas remains unclear.
In the current study, the expression of FOXO4 was significantly different between patients with LGGs with and without a history of seizures. High expression of FOXO4 was associated with a decreased risk of seizure occurrence in patients with LGGs. This result was confirmed in the TCGA dataset. As FOXO4 was found to be a suppressor of tumor growth and proliferation, which change the peri-tumoral environment, it may be involved in epileptogenesis. Moreover, the high expression of FOXO4 may inhibit tumor growth and decrease the risk of seizure occurrences secondary to the tumor invasion. The underlying mechanism of the association of other identified genes with seizure occurrences is still unclear.
Various clinical risk factors for glioma-induced seizures have been reported in different populations [5, 23, 36] . Therefore, it is important to consider whether the molecular mechanisms of tumor-related seizures are the same between different populations. The CGGA database contains the genomic information from the gliomas of many east Asian individuals, and the TCGA database contains the genetic information of gliomas from mostly Caucasian individuals [37] . In this study, using the CGGA database, we found that FOXO4 expression was associated with a risk of seizures in patients with LGGs, and this result was validated using data from the TCGA database. Our results revealed the consistent involvement of FOXO4 in tumor-related seizures between populations.
We also examined the role FOXO4 expression plays in the seizure outcomes in patients with LGGs. We found that high FOXO4 expression was associated with a reduced Engel classification at 6 months after tumor resection. This result suggested that FOXO4 could potentially be used to predict seizure outcomes.
Several limitations of our analysis should be noted. First, information about the patients' overall survival time was only available for half of the LGG cases owing to the relatively long survival of the patients. Second, the number of LGG samples that were available for the RNA sequencing assessments in the CGGA database were limited. Therefore, we used the TCGA dataset as a validation group. Future studies should explore the value of FOXO4 as a potential therapeutic target for tumor-associated epilepsy.
Conclusions
The current study identified an association between FOXO4 expression and epileptic seizures in patients with LGGs. High FOXO4 expression was linked to a decreased risk of seizure occurrences and a better seizure outcome. Our findings promote the understanding of the mechanisms underlying the origin of seizures in patients with LGGs and may provide important information that could be used to customize the seizure treatments in these patients.
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